UNSPSC 51334416: Roxoperone

This classification denotes an anxiolytic with the molecular formula C19H23FN2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5RS1CY853F, chemically known as 2,8-diazaspiro(4.5)decane-1,3-dione, 8-(4-(4-fluorophenyl)-4-oxobutyl)-2-methyl- (9ci) but generally known as roxoperone, which bears US NIH Compound Identifier 71117. European Medicines Agency schedules Roxoperone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10402MIG. The term ROXOPERONE is an International Non-Proprietary Name.

UNSPSC 51334416 Roxoperone, a Commodity-level code, covers pharmaceutical products and related systems procured by state and local health agencies, though recent activity under this specific code shows limited direct alignment with the nominal product name. State and local governments are buying naloxone systems, generic pharmaceuticals through cooperative purchasing agreements, and direct-to-manufacturer prescription program capabilities under related pharmaceutical procurement vehicles. The issuing bodies include county health departments, state health and human services agencies, and regional cooperative purchasing alliances administering multi-state pharmaceutical contracts. Seminole County, Florida, and the Texas Health and Human Services Commission represent the mix of single-jurisdiction and multi-jurisdiction procurement entities active in this space; the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) administers pharmaceutical procurement across multiple participating states and local government facilities.

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida posted IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries, with bids due July 26, 2023. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescriptions program, signaling exploratory market intelligence work before formal procurement. MMCAP posted RFP S1070000015802 on January 20, 2026, to establish multi-award contracts for generic multi-source pharmaceuticals and OTC products across state and local facilities in Minnesota, Oregon, and other participating jurisdictions, with proposals due March 26, 2026, and contract effectiveness July 1, 2026. Cooperative purchasing vehicles dominate the landscape for broader pharmaceutical supply; single-jurisdiction buys focus on emergency-response and community health products. Vendors must comply with FDA requirements, Drug Supply Chain Security Act certification, current Good Manufacturing Practices, E-Verify confirmation, and insurance requirements ranging from $2 million to $5 million depending on scope.